Merck & Premier Inc. join hands to reduce C. diff recurrence
Category: #health  By Dhananjay Punekar  Date: 2018-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck & Premier Inc. join hands to reduce C. diff recurrence

Merck & Co., a U.S. based pharmaceutical giant, and Premier Inc., have reportedly extended their partnership on preventative & chronic ailment care for minimizing the recurrence of the Clostridium difficile infection. Sources cite that both the Merck and Premier are expected to offer support, education, and consultation to patients suffering from C. diff.

The strategic move is aimed at increasing the awareness level of the patients for reducing the recurrence of the infectious ailment and facilitating easy access of healthcare services for the patients. For the record, both the healthcare firms have been carrying out research activities for preventing the disease recurrence in the subjects.

According to CDC (Centers for Disease Control and Prevention), the elaborate use of antibiotic medicines or long-term C. diff infection is one of the main causes of healthcare-related infections across the U.S. Estimates claim that nearly half a million of the U.S. population are affected due to the infection, with patients consuming antibiotics more prone to get infected from the ailment.

C.diff accounts for nearly USD 4.8 billion of the country’s healthcare expenditure each year. Data statistics have revealed that one out of five patients experience the recurrence of the disease.

Raquel Tapia, Associate Vice President of Specialty Marketing at Merck, has announced that the integration of Premier Inc.’s tech abilities and therapeutic knowledge of Merck will help the patients effectively handle their healthcare challenges. Reportedly, the C. diff intervention is projected to be tested at the Premier member health systems.

It has been predicted that the extension of the business relationships will make a big difference in resolving the critical public health issues of the patients across the globe.

For the uninitiated, Premier Inc., is one of the leading healthcare improvement companies that encompasses close to 3,900 U.S. hospitals and health systems in addition to a mammoth 150,000 other providers.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...